Marker Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $23.18M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Mar 19, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | Before market open | $1.23M | $-0.12 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | $1.93M | $-0.26 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | During market hours | $1.24M | $-0.27 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 26, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | During market hours | $257.61K | $-0.34 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | During market hours | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 22, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 10, 2022 | During market hours | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 11, 2022 | During market hours | – | – | – |
Press releases
Announcements Marker Therapeutics filed with the SEC
Marker Therapeutics Awarded $2.6 Million FDA
Other events · EX-99.1 to Form 8-K
Marker Therapeutics Reports Year-End 2025 Corporate
Results of operations · EX-99.1 to Form 8-K
Reports Third Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Marker Therapeutics appoints Kathryn Penkus
Executive or director change · Other events · EX-99.1 to Form 8-K
Marker Therapeutics Announces First Patient
Other events · EX-99.1 to Form 8-K
Marker Therapeutics Provides Update on Phase
Regulation FD disclosure · EX-99.1 to Form 8-K
MARKER THERAPEUTICS CORPORATE PRESENTATION August 2025 NASDAQ: MRKR
Regulation FD disclosure · EX-99.2 to Form 8-K
MARKER THERAPEUTICS CORPORATE PRESENTATION August 26, 2025 NASDAQ: MRKR
Regulation FD disclosure · EX-99.3 to Form 8-K
Marker Therapeutics and Cellipont Bioservices
Material agreement · Other events · EX-99.1 to Form 8-K
Marker Therapeutics Reports that Lymphodepletion
Other events · EX-99.1 to Form 8-K
Marker Therapeutics Reports Year-End 2024 Corporate
Results of operations · EX-99.1 to Form 8-K
Marker Therapeutics Provides a Clinical Update
Material agreement · Other events · EX-99.1 to Form 8-K
Marker Therapeutics Announces $16.1 Million
Material agreement · Other events · EX-99.2 to Form 8-K
Marker Therapeutics Awarded $9.5 Million Grant
Other events · EX-99.1 to Form 8-K
Reports Third Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Marker Therapeutics Reports Second Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Marker Therapeutics Awarded $2 Million Grant
Other events · EX-99.1 to Form 8-K
Marker Therapeutics Reports First Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Principal Investigator from City of Hope National
Other events · EX-99.1 to Form 8-K
Marker Therapeutics Reports Year-End 2023 Corporate
Results of operations · EX-99.1 to Form 8-K
Marker Therapeutics Announces Clinical Program
Regulation FD disclosure · EX-99.1 to Form 8-K
as amended, and Section 27A of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended,
Regulation FD disclosure · EX-99.2 to Form 8-K
Marker Therapeutics Announces Sustained Complete
Other events · EX-99.1 to Form 8-K
Marker Therapeutics Reports Third Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Marker Therapeutics Announces Complete Response
Other events · EX-99.1 to Form 8-K
Marker Therapeutics Reports Second Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Marker Therapeutics Reports Non-Clinical Proof-of-Concept
Regulation FD disclosure · EX-99.1 to Form 8-K
European Medicines Agency Grants Orphan Drug
Regulation FD disclosure · EX-99.1 to Form 8-K
Marker Therapeutics Reports MT-401 Non-Clinical
Regulation FD disclosure · EX-99.1 to Form 8-K
Marker Therapeutics Announces First Lymphoma
Regulation FD disclosure · EX-99.1 to Form 8-K
Marker Therapeutics Reports Pre-Clinical Data
Regulation FD disclosure · EX-99.1 to Form 8-K
Marker Therapeutics Appoints Monic Stuart, M.D.,
Regulation FD disclosure · EX-99.1 to Form 8-K
TO EXTEND MARKER’S FINANCIAL RUNWAY
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Marker Therapeutics Reports Fiscal Year 2022
Results of operations · EX-99.1 to Form 8-K
Marker Therapeutics and Lincoln Park Capital
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Marker Therapeutics Announces FDA Clearance
Regulation FD disclosure · EX-99.1 to Form 8-K
Marker Therapeutics Reports Q3 2022 Operating
Results of operations · EX-99.1 to Form 8-K
Marker Therapeutics Awarded $2 Million Grant
Regulation FD disclosure · EX-99.1 to Form 8-K
Marker Therapeutics Reports Q2 2022 Operating and Financial Results
Results of operations · EX-99.1 to Form 8-K
Marker Therapeutics Announces FDA Clearance
Regulation FD disclosure · EX-99.1 to Form 8-K